Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-cash Items (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Non-cash Items for 12 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items changed N/A to $1000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1000.0, a N/A change, with the full-year FY2025 number at $1000.0, changed N/A from a year prior.
  • Non-cash Items was $1000.0 for Q4 2025 at Anika Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $4.7 million in Q3 2021 to a low of $1000.0 in Q2 2025.
  • A 5-year average of $574000.0 and a median of $188000.0 in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: surged 6922.22% in 2023, then crashed 99.67% in 2025.
  • Anika Therapeutics' Non-cash Items stood at $975000.0 in 2021, then rose by 7.69% to $1.0 million in 2022, then crashed by 87.9% to $127000.0 in 2023, then surged by 95.28% to $248000.0 in 2024, then tumbled by 99.6% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Non-cash Items are $1000.0 (Q4 2025), $1000.0 (Q2 2025), and $248000.0 (Q3 2024).